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Abstract. The serine protease cathepsin G (CatG) is involved 
in numerous processes associated with the innate and adap-
tive immune system. During an immune response, neutrophils 
secrete CatG, which can bind to the cell surface of immune 
cells to provoke the proteolytic processing of cytokines and 
chemokines in order to stimulate lymphocytes. The present 
study analyzed peripheral blood mononuclear cells to charac-
terize T cell populations in terms of their CatG content by flow 
cytometry. It was identified that CatG was exclusively present 
on the cell surface of a subset of T regulatory cells (Tregs), 
cluster of differentiation (CD) 39+ Tregs, which expressed 
CatG in contrast to CD39- Tregs. Additionally, CatG was 
expressed on double positive CD4+CD8+ T cells, T helper (Th) 
9 cells and Th22 cells, implicating CatG as a novel marker to 
distinguish certain T cell subsets.
Introduction
Organisms are constantly exposed to diverse and harmful 
factors. As they are exposed to a surrounding environment 
containing bacteria, viruses and fungi, in addition to 
multicellular parasites, it is important that complex organisms 
develop efficient and specialized defense mechanisms. The 
innate immune system, which includes neutrophils, acts 
as the first line of contact against potential pathogens. By 
contrast, B cells, cytotoxic T lymphocytes and cluster of 
differentiation (CD) 4+ T cells represent the majority of 
immune cells within the adaptive immune system, which is 
characterized by different properties, including a variety 
of antigen-specific receptors (B and T cell receptors) and 
immunological memory (1). Antigenic peptides loaded to 
major histocompatibility complex (MHC) class I molecules 
are detected by CD8+ T cells; whereas macrophages, dendritic 
cells (DCs) and B cells, as professional antigen-presenting 
cells (APCs), display antigenic peptides to MHC II molecules, 
leading to CD4+ T cell activation when foreign antigens 
are recognized by these cells (2). CD4+ T cells are capable 
of differentiating into several types of T helper (Th) cells, 
including Th1, Th2, Th9, Th17 and Th22 cells, and execute 
distinct effector functions during an immune response (1). 
For example, Th1 cells detect intracellular pathogen‑derived 
antigens, Th2 and Th9 cells defend against parasites, Th17 
cells recognize fungi and extracellular bacteria, and Th22 
cells serve as a defense against microbial infections of the 
skin (3-5).
T regulatory cells (Tregs) are essential for maintaining 
an immune response, immune homeostasis, and tolerance. 
Approximately 5% of CD4+ T cells are Tregs in normal human 
peripheral blood. Tregs are divided into thymus-derived 
natural Tregs, induced Tregs generated by transforming 
growth factor‑β and interleukin (IL)‑2 in vitro, and peripheral 
Tregs (6). CD39+ Tregs express the ectonucleotidases CD39 
and CD73; CD39 hydrolyzes extracellular ATP and ADP to 
generate AMP, and CD73 further converts AMP to adenosine, 
which binds to cell surface A2A receptor of effector cells 
and thereby suppresses a T cell response (7-10). Notably, 
antigen‑specific Tregs express the co‑stimulatory molecule 
CD134 (11,12).
Cathepsin G (CatG) belongs to the family of serine prote-
ases. Due to the structural properties of the active center, 
which contains a catalytic triad consisting of histidine, aspar-
tate and serine amino acids (13), CatG exhibits chymotrypsin 
and trypsin-like enzymatic activity with a broad substrate 
specificity (14,15). CatG and lactoferrin (LF), among other 
serine proteases, are released by activated neutrophils during 
an immune response (16). Of note, a previous study by our 
group identified that LF increased the activity of CatG and 
lowered its substrate specificity, and the combined action of 
LF and CatG increased the activation status of human plate-
lets (17). Furthermore, CatG exhibit an antibacterial capacity, 
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indicated by the positive charge of sufficient arginine residues 
within the CatG protein sequence (18) and is a component 
of the so‑called neutrophil extracellular traps, as CatG has, 
compared with other serine proteases, a notably high affinity 
towards deoxyribonucleic acid (19,20). In addition to the acti-
vation of specific cytokines to modulate an immune response, 
CatG is able to inactivate cytokines, including IL-2 and IL 
6, and the growth and maturation factor CXC chemokine 
stromal cell-derived factor 1 (SDF1) (21). Additionally, CatG 
has been detected on the cell surface of different immune 
cells, namely neutrophils (22), B cells, natural killer (NK) 
cells (23) and platelets (24), and low levels of CatG have 
been detected on CD4+ T cells (23). Previously, our group 
demonstrated that distinct NK cell subsets (CD16-CD56dim and 
CD16dimCD56-) possessed proteolytic active CatG on their cell 
surface in contrast to other NK cell subsets (CD16-CD56bright, 
CD16dimCD56bright, CD16brightCD56dim, CD16dimCD56dim, and 
CD16brightCD56-) (25). However, which T cell subsets carry 
CatG, and whether CatG can be detected on Tregs, was not 
determined. Therefore, the present study analyzed peripheral 
blood mononuclear cells (PBMCs) for their cell surface CatG 
content, and identified that CD4+CD8+ T cells, Th9 cells, Th22 
cells and CD39+ Tregs, but not CD39- Tregs, harbored CatG at 
the cell surface, implicating CatG as a novel marker for these 
cells.
Materials and methods
Sample collection and preparation. Freshly purified or 
cryopreserved PBMCs from healthy male or female donors, 
young donors between 18-25 years and elderly donors between 
59-70 years (collected between 2015 and 2016; gender ratio: 
female:male, 50:50), were analyzed. The PBMCs from buffy 
coats, obtained from the DRK Blood Donation Center, 
Baden‑Württemberg‑Hessen; Institute Ulm (Ulm, Germany), 
were purified using Ficoll density centrifugation (Ficoll‑Pague 
PLUS, GE Healthcare, Little Chalfont, UK). The blood donors 
were informed with regard to the use of their blood cells for 
research purposes and their consent was obtained. Briefly, 
25 ml of a 1:10 phosphate‑buffered saline (PBS, pH 7.4, Gibco; 
Thermo Fisher Scientific, Inc., Waltham, MA, USA) buffy 
coat dilution was carefully added to the Ficoll solution (15 ml), 
which was prepared in a 50-ml centrifuge tube, and centri-
fuged (750 x g for 20 min at room temperature). Following 
centrifugation, PBMCs were cautiously collected from the 
Ficoll interface, washed three times with PBS, and prepared 
for flow cytometric analysis. In case of later usage of PBMCs, 
1x107 cells were stored in fetal bovine serum (FBS, Gibco; 
Thermo Fisher Scientific, Inc.) with 10% dimethyl sulfoxide 
(DMSO, Serva Electrophoresis GmbH, Heidelberg, Germany) 
at ‑80˚C.
Detection of CatG on the cell surface of different T cell 
subsets. The cryopreserved PBMCs were thawed, washed 
twice with PBS and adjusted to a final concentration of 
5x106 PBMCs/ml. Subsequently, the PBMCs were stained 
with anti-CD25-APC (4 µg/ml; BC96; Thermo Fisher 
Scientific, Inc.), anti‑CD4‑APC/Cy7 (4 µg/ml; RPA‑T4; BD 
Biosciences, Franklin Lakes, NJ, USA), anti-CD8-PerCP 
(4 µg/ml; SK1; BD Biosciences), anti-C-C-chemokine receptor 
type 10 (CCR10)-APC (2.5 µg/ml; 6588-5; BioLegend, 
Inc., San Diego, CA, USA), anti‑CD4‑Alexa Fluor 700 
(4 µg/ml; OKT4; eBioscience; Thermo Fisher Scientific, 
Inc.), anti-CD39-PerCP/Cy5.5 (2 µg/ml; A1; BioLegend, 
Inc.), anti-CD127-PE/Cy7 (4 µg/ml; A019D5; BioLegend, 
Inc.), anti-CD134-PE (4 µg/ml; Ber-ACT35; BioLegend, 
Inc.), anti‑CD183‑PE (5 µg/ml; G025H7; BioLegend, Inc.), 
anti‑CD194‑PerCP/Cy5.5 (2.5 µg/ml; L291H4; BioLegend, 
Inc.), anti-CD196-PE/Cy7 (5 µg/ml; G034E3; BioLegend, 
Inc.), anti-human CatG-FITC (2 µg/ml; ABIN5565299; Acris 
Antibodies GmbH, Herford, Germany), or isotype control for 
CatG (2 µg/ml; ABIN96440; Acris Antibodies GmbH). The 
PBMCs were diluted in PBS (pH 7.4) containing 1% FBS 
and incubated with the respective antibody set for 30 min 
at 4˚C. Following incubation, the PBMCs were washed, 
collected by a FACSCanto II cytometer (BD Biosciences), and 
analyzed using FlowJo software version 7.6.5 (FlowJo LLC, 
Ashland, OR, USA). The compensation was performed using 
unstained and single stained PBMCs by using the respective 
antibody and was calculated using FACSDivaTM software (BD 
Biosciences). Flow cytometric analysis and antibody selection 




Statistical analysis. Statistical analysis was performed with 
GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, 
USA). Data are presented as standard error of the median and 
statistical analysis was performed using one-way analysis of 
variance and the Bonferroni correction. The use of PBMCs for 
in vitro experiments was approved by the Ethics Committee of 
Ulm University (Ulm, Germany; proposal no. 327/14).
Results
CatG is present on double positive CD4+CD8+ T cells, Th9 
cells and Th22 cells. Double positive CD4+CD8+ T cells are 
present in small numbers in the peripheral blood (26,27) 
and their function remains a source of debate; for example, 
these cells exhibit an antiviral activity (28) but have also 
been implicated in several pathological conditions, including 
autoimmunity (29,30) and cancer (31). To determine whether 
these cells express cell surface CatG, PBMCs were gated for 
CD8+ T cells, CD4+ T cells and double positive CD4+CD8+ 
T cells, and the levels of cell surface CatG were analyzed. 
CatG was not detected on the cell surface of CD8+ T cells, as 
illustrated in Fig. 1A and B. This is in accordance with previ-
ously published data demonstrating that CatG was absent on 
CD8+ T cells (23,32). In contrast to the CD8+ T cells, CatG 
was identified on the cell surface of CD4+CD8+ T cells and 
on CD4+ T cells; however, the obtained data for CD4+ T cells 
did not reach statistical significance. These results correlate 
with previously published data indicating that only low levels 
of CatG can be detected on CD4+ T cells (23). Collectively, 
these findings suggest that the cell surface expression of CatG 
differs between CD4+ T cell subsets and that only a subpopula-
tion may be positive for CatG. To examine this further, a panel 
of Th subsets was analyzed. Subpopulations of Th1, Th2, Th9, 
Th17, and Th22 cells were distinguished by a combination of 
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essential cell surface markers. An overview of the different 
antibodies used to identify Th subsets, namely CD4, CD183, 
CD194, CD196 and CCR10 antibodies, is shown in Fig. 1C. 
Notably, Th9 and Th22 cells carried cell surface CatG, whereas 
the analysis did not detect any CatG on Th1, Th2, or Th17 cells 
(Fig. 1D). Taken together, these findings suggest that CatG is 
present on the cell surface of double positive CD4+CD8+ T 
cells, Th9 cells, and Th22 cells.
CatG is expressed on the cell surface of CD39+ Tregs. Tregs 
are a heterogenic cell population. However, two subsets can 
be distinguished by their CD39 expression status, namely as 
CD39+ and CD39- Tregs (11). The CD39+ Treg subpopulation 
has a higher immune-suppressing capacity compared with 
CD39- Tregs (8,9,33). In order to phenotype CD39+ Tregs 
from viable singlets, cells were identified by an antibody panel 
recognizing cell surface CD4, CD127, CD25, CD134, and 
CD39 molecules (34). These CD4+ T cells, which exhibit a low 
expression of CD127 and high expression of CD25 (35), were 
further gated for CD134+, and the two groups of CD39- and 
CD39+ Tregs were investigated (data not shown). Notably, 
CD39+ Tregs did express CatG on the cell surface, whereas 
cell surface CatG was absent on CD39- cells (Fig. 1E and F). 
In addition, a small demographic donor group of CD39+ and 
Figure 1. Analysis of CatG on the cell surface of PBMCs. (A) Cell populations were determined by the expression of CD4 and CD8 in combination with the 
expression of CatG. Double positive CD4+CD8+ T cells, CD4+ T cells, and CD8+ T cells were detected and shown as one representative figure. (B) Expression 
levels of CatG on the indicated cells are summarized in the bar diagram (n=10). (C) Analysis of the activity of CatG on the cell surface of Th cell subsets. 
(D) Th1, Th2, Th9, Th17, and Th22 cells were detected, and cell surface expression of CatG was compared via flow cytometry. Th1 cells were deter-
mined by CD183+CD194-CD96-CCR10- expression, Th2 cells by CD183-CD194+CD196-CCR10-, Th9 cells by CD194-CD196+ expression, Th17 cells by 
CD183-CD194+CD196+CCR10- expression, and Th22 cells by CD183-CD194+CD196+CCR10+ expression (n=10). (E) Detection of CatG at the cell surface of 
Tregs. CD39- and CD39+ Tregs were compared for their cell surface expression of CatG by using flow cytometry. Cells were gated for CD127dimCD4+CD25+ 
and the remaining cells (CD39 vs. CD134) were split into Treg cell subsets (CD39- and CD39+ Tregs). (F) Levels of CatG on CD39- and CD39+ Tregs were 
analyzed in 37 healthy donors. For comparison, the MFI was used. The data were normalized to the isotype control and MFI values are expressed as the 
standard error of the median. Significant differences were calculated by one‑way analysis of variance and the Bonferroni correction. **P<0.01 and ****P<0.0001. 
CatG, cathepsin G; CD, cluster of differentiation; CCR, C‑C chemokine receptor; Th, T helper; Tregs, T regulatory cells; MFI, median fluorescence intensity.
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CD39- Tregs was compared; however, no difference in the 
cell surface expression of CatG was observed when young 
and elderly donors were compared (data not shown). Taken 
together, these findings demonstrate that CD39+ Tregs harbor 
CatG on the cell surface, in contrast to CD39- Tregs.
Discussion
During an inflammatory response, neutrophils secrete CatG 
into the extracellular space to propagate innate and adaptive 
immune response (16). When simulating an immune response, 
a previous study indicated that exogenous CatG binds to CD4+ 
T cells, CD8+ T cells, NK cells, and B cells (32). Although these 
findings were not determined for CD8+ T cells when excess 
quantities of CatG were added to the assay (23), the authors 
identified that the growth and maturation factor CXC chemo-
kine SDF1, being key for an inflammatory response (21), was 
proteolytically inactivated by CatG present on the cell surface 
of B cells, NK cells, and weakly on CD4+ T cells (23). The 
aforementioned results are of particular interest as Tregs are 
responsible for terminating an immune response (36). In turn, 
the data obtained in the present study suggest that cell surface 
CatG may support Treg cell function to maintain immune 
homeostasis.
In our previous study, it was demonstrated that DCs from 
CatG‑deficient mice expressed lower levels of cell surface 
MHC I molecules compared with their wild‑type counterparts. 
Furthermore, CatG provokes the upregulation of cell surface 
MHC I molecules on PBMCs and on human glioblastoma 
cells. Notably, cell surface CatG from PBMCs induces the 
expression of MHC I on the THP‑1 monocytic cell line (37). In 
consideration of our previously published data and the finding 
that non-activated CD4+CD8+ T cells expressed CatG on their 
cell surface, it may be hypothesized that CD4+CD8+ T cells 
provoke an upregulation of MHC I on their target cell in order 
to monitor the intracellular peptide status via MHC I. In case 
of an altered MHC I‑peptide repertoire, CD4+CD8+ T cells 
may act via their specialized function, which is potentially 
important for an immune response.
Migration and infiltration purposes of CD4+CD8+ T cells, 
Th9 cells, Th22 cells, and CD39+ Tregs may be an additional 
reason for the presence of CatG at the cell surface. It is well 
known that matrix metalloproteinases are not the only essential 
enzymes in extracellular matrix (ECM) remodeling and cell 
migration; serine proteases, including CatG, are also capable 
of degrading the ECM (38). It is possible that CD4+CD8+ 
T cells, Th9 cells, Th22 cells, and CD39+ Tregs reach their 
destination more efficiently than non‑CatG expressing T cells. 
The significance of CatG on CD39+ Tregs and its biological 
function can be analyzed by the application of a specific CatG 
inhibitor, potentially eliciting the modulation of T cell migra-
tion. The use of flow cytometry to detect CatG has limitations, 
additional methods are required in order to further examine 
CatG and its potential role in the support or regulation of an 
immune response.
In conclusion, the present study used a direct 
FITC-conjugated anti-CatG antibody to perform the assay, 
which was found to be advantageous for the rapid analysis of 
immune cells compared with the unconjugated anti-CatG anti-
body used in previous studies (23,32). Furthermore, CatG may 
be considered as a novel cell surface marker of CD4+CD8+ T 
cells, Th9 cells, Th22 cells, and CD39+ Tregs.
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